Key facts
- This page summarizes James E. Levine's Form 4 filing for Cardiff Oncology, Inc. (CRDF).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 12 Jul 2021, 16:16.
James E. Levine - 12 Jul 2021 Form 4 Insider Report for Cardiff Oncology, Inc. (CRDF)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- CRDF
- Reported as of
- 12 Jul 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 12 Jul 2021, 16:16:15 UTC
- Next SEC filing
- 13 Sep 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ James Levine
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
James E. Levine filed Form 4 for Cardiff Oncology, Inc. (CRDF) on 12 Jul 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRDF
transaction
Derivative
Common Stock
Award
- Transaction value
- $0
- Shares
- +390,000
- Change %
- Price
- $0.000000
- Shares after
- 390,000
- Date
- 12 Jul 2021
- Ownership
- Direct
- Underlying class
- Stock Options
- Underlying amount
- 390,000
- Exercise price
- $6.55
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
97,500 vest on 7/12/2022. 8,125 vest monthly for 36 months beginning on 8/12/2022 through 7/12/2025.